Joseph Pearlberg - Infinity Pharmaceuticals Insider

Infinity Pharmaceuticals Inc -- USA Stock  

USD 2.9  0.05  1.69%

Vice President - Clinical Development

Dr. Joseph Pearlberg, M.D. Ph.D., serves as Vice President Clinical Development of the Company
  President Since 2017  Ph.D    
Joseph Pearlberg joined Infinity in 2014 and has 25 years of experience in research and medicine. Prior to joining Infinity, Dr. Pearlberg worked at Sanofi from 2010 to 2014 where he held various roles of increasing responsibility within the clinical development organization. Prior to that, Dr. Pearlberg held a postdoctoral fellowship at Harvard Medical School from 2002 to 2010. During his career, he also held various medical and research positions at Dana Farber Cancer Center and Massachusetts General Hospital. Additionally, Dr. Pearlberg was a Genentech Research Fellow from 1997 to 1999. He earned a M.D. from University of California, San Francisco, a Ph.D. in molecular biology from Harvard University and a B.A. from University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of (26.58) % which means that it has lost $26.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (78.61) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficulttotreat diseases. Infinity Pharmaceuticals Inc (INFI) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 48 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Headlines Timeline Now

Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Hide  View All  Next  Launch Headlines Timeline
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Infinity Pharmaceuticals Inc to your portfolio

Top Management

Infinity Pharmaceuticals Leadership Team
Joseph Pearlberg, President, Ph.D
Melissa Hackel, President, MBA
William Bertrand, President
Vito Palombella, EVP
Jeffrey Berkowitz, Director
Lawrence Bloch, President, MBA
Norman Selby, Director, MBA
Jose Baselga, Director, Ph.D
Michael Venuti, Director, Ph.D
Franklin Moss, Executive
David Roth, Executive
Michael Kauffman, Director
Jaren Madden, Director
Eric Lander, Director, Ph.D
Julian Adams, President
Anthony Evnin, Director, Ph.D
Winston Lam, President, MBA
Gwendolyn Fyfe, Director
Sujay Kango, President, MBA
Ian Smith, Director
Adelene Perkins, Chairman, MBA

Stock Performance

Infinity Pharmaceuticals Performance Indicators